Tag Archives: biopharmaceuticals
By Guest Blogger | Published: June 17, 2014
By Emily O’Connor, Jillian Scaife, and Ryan P. Million Biopharmaceutical drug discovery companies have progressively tailored their pipelines to specialty therapeutic areas and smaller patient populations. However, the specialty business model has lately shown signs of strain and outright constraints in continued scalability. Agents such as Gleevec, Zaltrap, and Sovaldi have been under fire from […]
By Guest Blogger | Published: April 15, 2014
Overall, last year can be considered quite a successful one in terms of new product approvals. Nineteen products containing new biopharmaceutical molecular entities were approved in the United States and/or the European Union. These approval numbers are above average compared to the previous five years, which recorded a mean approval rate of 13 products. The […]
By Pharm Exec | Published: March 28, 2014
Baxter International plans to create two separate, independent global healthcare companies, with one focused on biopharmaceuticals and the other on medical products.
By Pharm Exec | Published: February 13, 2014
Accenture has launched the latest version of its annual study of the biopharmaceutical industry. The High Performance Business (HPB) report analyses the long-term performance of the 16 largest pharma companies globally, highlighting industry trends, pharmaceutical business performance analysis, and potential implications for the industry.
By Guest Blogger | Published: February 10, 2012
By Amy Ritter, Pharmaeutical Technology. A report released on Feb. 8, 2012 from the California Healthcare Institute, BayBio and PwC shows that the shrinking economy, changes in investment strategies, and pressures on the pharmaceutical market have put the brakes on one of the US’s most robust biotechnology centers. California had enjoyed steady growth in its […]